EXHIBIT 10.4

                        Millennium Pharmaceuticals, Inc.


                              Director Stock Option
                     GRANTED UNDER 2000 STOCK INCENTIVE PLAN


1. GRANT OF OPTION.

    This document evidences the grant by Millennium Pharmaceuticals, Inc.,
a Delaware corporation (the "Company"), on _______, _____ (the "Grant Date") to
_________________, a director of the Company (the "Participant"), of an option
to purchase, in whole or in part, on the terms provided herein and in the
Company's 2000 Stock Incentive Plan (the "Plan"), a total of ________________
shares (the "Shares") of common stock, $.001 par value per share, of the Company
("Common Stock") at $________ per Share. Unless earlier terminated, this option
shall expire on _______________ (the "Final Exercise Date").

    It is intended that the option evidenced by this document shall not be
an incentive stock option as defined in Section 422 of the Internal Revenue Code
of 1986, as amended and any regulations promulgated thereunder (the "Code").
Except as otherwise indicated by the context, the term "Participant", as used in
this option, shall be deemed to include any person who acquires the right to
exercise this option validly under its terms.

2. VESTING SCHEDULE.

    Subject to Section 3 below, this option will become exercisable ("vest") as
follows:

         -------------------------------------------------------------------

         -------------------------------------------------------------------.

    The right of exercise shall be cumulative so that to the extent the
option is not exercised in any period to the maximum extent permissible it shall
continue to be exercisable, in whole or in part, with respect to all Shares for
which it is vested until the earlier of the Final Exercise Date or the
termination of this option under Section 3 hereof or the Plan.

3. EXERCISE OF OPTION.

     (a) FORM OF EXERCISE. Each election to exercise this option shall be in
writing in the form attached to this document, signed by the Participant, and
received by the Company at its principal office, accompanied by payment in full
in the manner provided in the Plan. The Participant may purchase less than the
number of Shares covered hereby, provided that no partial exercise of this
option may be for any fractional share.

     (b) CONTINUOUS RELATIONSHIP WITH THE COMPANY REQUIRED. Except as otherwise
provided in this Section 3, this option may not be exercised unless the
Participant, at the time he or she exercises this option, is, and has been at
all times since the Grant Date, an employee, officer or director of, or
consultant or advisor to, the Company or any parent or subsidiary of the Company
as defined in Section 424(e) or (f) of the Code (an "Eligible Participant").

     (c) TERMINATION OF RELATIONSHIP WITH THE COMPANY. If the Participant ceases
to be an Eligible Participant for any reason, then the right to exercise this
option shall terminate three months after such cessation, or at the end of such
longer period as provided in paragraphs (d) and (e) below, but in no event after
the Final Exercise Date. In this circumstance, this option shall be exercisable
only to the extent that the Participant was entitled to exercise this option on
the date of such cessation. The rights provided in this paragraph are subject to
the limitations provided in paragraph (f) below.

     (d) EXERCISE PERIOD UPON DISABILITY. If the Participant becomes disabled
(within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise
Date while he or she is an Eligible Participant, this option shall be
exercisable within the period of one year following the date of disability of
the Participant, but in no event after the Final Exercise Date. In this
circumstance, this option shall be exercisable only to the extent that the
Participant was entitled to exercise this option on the date of his or her
disability. The rights provided in this paragraph are subject to the limitations
provided in paragraph (f) below.

     (e) EXERCISE PERIOD UPON DEATH. If the Participant dies prior to the Final
Exercise Date while he or she is an Eligible Participant, this option shall
become immediately exercisable in full and shall be exercisable within the
period of three years following the date of death of the Participant, but in no
event after the Final Exercise Date. The rights provided in this paragraph are
subject to the limitations provided in paragraph (f) below.

     (f) BREACH OF OBLIGATIONS; DISCHARGE FOR CAUSE. If the Participant, prior
to the Final Exercise Date, violates the non-competition or confidentiality
provisions of any employment, consulting or advisory contract, confidentiality
and nondisclosure agreement or other agreement between the Participant and the
Company, the right to exercise this option shall terminate immediately upon
written notice to the Participant from the Company describing such violation.

     If the Participant's relationship with the Company is terminated prior to
the Final Exercise Date by the Company for "cause" (as defined below), the right
to exercise this option shall terminate immediately upon the effective date of
such termination. "Cause" shall mean willful misconduct by the Participant or
willful failure by the Participant to perform his or her responsibilities to the
Company (including, without limitation, breach by the Participant of any
provision of any employment, consulting, advisory, nondisclosure,
non-competition or other similar agreement between the Participant and the
Company), as determined by the Company, which determination shall be conclusive.
The Participant shall be considered to have been discharged for "Cause" if the
Company determines, within 30 days after the termination of the Participant's
relationship with the Company, that termination of the relationship for cause
was warranted.

4. WITHHOLDING.

     No Shares will be issued pursuant to the exercise of this option unless and
until the Participant pays to the Company, or makes provision satisfactory to
the Company for payment of, any federal, state or local withholding taxes
required by law to be withheld in respect of this option.
5. TRANSFERABILITY OF OPTION.

     Except as otherwise provided in this Section, this option is not
transferable other than by will or the laws of descent and distribution, and
this option may be exercised, during the lifetime of the Participant, only by
the Participant. However, the Participant may transfer this option for no
consideration to or for the benefit of the Participant's Immediate Family
(including, without limitation, to a trust for the benefit of the Participant's
Immediate Family or to a partnership or limited liability company for one or
more members of the Participant's Immediate Family) and the transferee shall
remain subject to all the terms and conditions applicable to this option prior
to such transfer. The foregoing right to transfer this option shall apply to the
right to consent to amendments of the terms of this option. The term "Immediate
Family" shall mean the Participant's spouse, parents, children, stepchildren,
adoptive relationships, sisters, brothers and grandchildren (and, for this
purpose, shall also include the Participant.)

6. PROVISIONS OF THE PLAN.

     This option is subject to the provisions of the Plan, a copy of which is
furnished to the Participant with this option.

     IN WITNESS WHEREOF, the Company has caused this option to be executed under
its corporate seal by its duly authorized officer. This option shall take effect
as a sealed instrument.


                               MILLENNIUM PHARMACEUTICALS, INC.


Dated:                         By: ___________________________________
                                   Mark J. Levin
                                   Chief Executive Officer and President